C12Y 204/01087
N-acetyllactosaminide 3-alpha-galactosyltransferase , i.e. alpha-1,3-galactosyltransferase
Official title: N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
C12Y204/01087 (N-acetyllactosaminide 3-alpha-galactosyltransferase , i.e. alpha-1,3-galactosyltransferase) appears on 16 US grants and 28 published applications in this corpus.
Search patents in C12Y- Granted patents
- 16
- Published applications
- 28
- Assignees
- 24
- Inventors
- 65
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 1 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 1 | 3 |
| 2017 | 1 | 3 |
| 2018 | 1 | 1 |
| 2019 | 3 | 2 |
| 2020 | 1 | 1 |
| 2021 | 1 | 3 |
| 2022 | 0 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 2 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof14 Jul 2026US 12,680,085 B2The University of Hong Kong
- Therapeutic compositions and methods of use for treating cancer2 Jul 2024US 12,023,362 B2Agalimmune Limited
- Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity15 Aug 2023US 11,725,044 B2Xenothera
- CRISPR/Cas9 vector combination and application thereof in gene knockout23 Nov 2021US 11,180,763 B2Nanjing Genefriend-Biotech Inc.
- Transgenic pig which simultaneously expresses HO-1 gene and TNFR1-Fc gene, and comprises knocked-out GGTA1 gene, and use thereof21 Jul 2020US 10,717,991 B2Chong Kun Dang Pharmaceutical Corp.
- Cancer immunotherapies to promote hyperacute rejection2 Jul 2026US 2026/0183409 A1Cornell University
- Cancer immunotherapies to promote hyperacute rejection13 Nov 2025US 2025/0345420 A1
- Viable galactosyltransferase knock-out sheep and related methods3 Jul 2025US 2025/0215450 A1Fios Therapeutics LLC
- Cancer immunotherapies to promote hyperacute rejection4 Jan 2024US 2024/0000959 A1Cornell University
- Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof21 Sep 2023US 2023/0295581 A1The University of Hong Kong
Most cited
By later US patents
- Xenotransplantation therapies42US 5,821,117 AThe Austin Research Institute · 1998
- Glycosyltransferase vectors for treating cancer25US 6,713,055 B2Geron Corporation · 2004
- Multi-transgenic pigs for diabetes treatment19US 9,339,519 B2Revivicor, Inc. · 2016
- Preparation and uses of gene sequences encoding chimerical glycosyltransferases with optimized glycosylation activity12US 8,993,297 B2Centre National De La Recherche Scientifique · 2015
- Selective antibody targeting of undifferentiated stem cells8US 6,921,665 B2Geron Corporation · 2005